Elsa Flores

Has grant

Associate Center Director, Basic Science

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Integrated Program in Cancer and Data Science

Open Date: 2019-09-16

Close Date: 2024-08-31

Grant: Close

Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma

Open Date: 2016-04-19

Close Date: 2023-03-31

Grant: Close

Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer

Open Date: 2012-05-01

Close Date: 2016-03-31

Grant: Close

Investigating the roles of p63 in miRNA regulation in EMT and metastatic breast cancer

Open Date: 2011-11-02

Close Date:

Grant: Close

Dissecting the complex roles of the p53 family in lymphoma

Open Date: 2011-07-01

Close Date: 2016-06-30

Articles (36)

Year:

2026

Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. Significance: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2–mTORC1–TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.

Year:

2026

There is growing interest in understanding the mechanisms underlying differences in cancer incidence among species (comparative oncology). The naked mole rat (NMR) is often referenced as “cancer resistant” and prior studies focused on identifying mechanisms explaining this. However, efforts to assess this in vivo have been limited. In this study, we provide evidence that the NMR presents as a novel autochthonous model of lung tumor initiation, driven by an introduction of the oncogenic Eml4-Alk fusion gene using CRISPR-mediated genome editing. Although in mice, the inversion alone is sufficient to drive tumorigenesis, the inversion alone was insufficient to drive tumorigenesis in the NMR lung, and tumor development required additional losses of the tumor suppressors p53 and pRb. Our findings suggest that the proposed “resistance” of the NMR to the development of cancer may reflect that the genetic events leading to tumor initiation are likely to be comparable with those present in human cells. Significance: To identify evolutionary divergent mechanisms of cancer resistance, we assessed tumorigenesis in vivo using the NMR, a species considered to exhibit cancer resistance. Our findings suggest that the proposed “resistance” of NMRs to the development of cancer may reflect tumor initiation mechanisms comparable with the mechanisms present in humans. See related commentary by Boddy and Abegglen, p. 7

Year:

2026

While immunotherapy has become the standard of care for lung adenocarcinoma (LUAD) patients without actionable genomic alterations, only a subset of patients benefits from a long-lasting response to immunotherapy. Activation of p53-related signals has emerged as a potential mediator of the lung tumor microenvironment (TME). Given that mutant-p53 interacts with p73 extensively and TAp73-deficient mice develop LUAD, we engineered a mouse model with conditional deletion of TAp73 to understand the interactions of the p53 family in the TME and in metabolic pathways that impact anti-tumor immunity. We demonstrated that TAp73 exerts a tumor-suppressive role in Kras G12D -driven LUAD by regulating lipid metabolism in the TME. We identified a TAp73-driven transcriptional signature involving genes in the arachidonic acid metabolism pathway operational in tumor-associated macrophages that favors T-cell activation and thus anti-tumor immunity. Similar transcriptional changes are seen in macrophages from LUAD patients with p53 mutations and in association with response to immunotherapy. SIGNIFICANCE There is a need to understand how the LUAD TME impacts patient response to immunotherapy. We identified a transcriptional program enacted by TAp73 in tumor alveolar macrophages that supports T-cell activation. Transcriptional and metabolomic data from LUAD patients supports the relevance of this program in response to immune checkpoint inhibition.

Year:

2025

Obesity and neurodegeneration are clinically associated diseases with defective autophagy. However, the genetic, biological, and metabolic underpinnings connecting these diseases are not well-understood. Here we identified a Mitochondria obesity/neurodegeneration (M on ) gene-signature that is shared between obesity, and neurodegenerative diseases. We demonstrate that, CEBPB elevates M on -gene-signature, to form podosomal belts, and enhance ROS production. Inhibiting autophagy collapses podosomal-belts through macropinocytosis to accumulate vacuoles, lipid-droplets, nuclear Notch-1 (nNICD), DEPTOR, and HBV-polymerase mRNAs. Conversely, hemin counteracts these events and suppresses DEPTOR and HBV-polymerase mRNAs by A-to-I-RNA-editing and nonsense-mediated decay. Furthermore, we CRISPR-engineered the antiviral chromosome-19 miRNA cluster (C19MC) to demonstrate that C19MC-miRNAs augment CEBPB, M on -gene-signature, ROS, and recapitulate CEBPB-driven phenotypes, in response to autophagy inhibition. Hemin, or a γ-Secretase inhibitor counteract these phenotypes in CRISPR-C19MC-engineered cells. Therefore, a CEBPB and C19MC-driven M on -gene-signature regulates the podosomal belt, lipid droplet, HBV, and DEPTOR mRNA dynamics to genetically link obesity, and neurodegeneration at the cellular level.

Year:

2025

Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. Significance: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2–mTORC1–TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.

Year:

2025

The p53 family member TP63 encodes two sets of N-terminal isoforms, TAp63 and ΔNp63 isoforms. They each regulate diverse biological functions in epidermal morphogenesis and in cancer. In the skin, where their activities have been extensively characterized, TAp63 prevents premature aging by regulating the quiescence and genomic stability of stem cells required for wound healing and hair regeneration, while ΔNp63 controls maintenance and terminal differentiation of epidermal basal cells. This functional diversity is surprising given that these isoforms share a high degree of similarity, including an identical sequence for a DNA-binding domain. To understand the mechanisms of the transcriptional programs regulated by each p63 isoform and leading to diverse biological functions, we performed genome-wide analyses using p63 isoform-specific chromatin immunoprecipitation, RNA sequencing, and metabolomics of TAp63−/− and ΔNp63−/− mouse epidermal cells. Our data indicate that TAp63 and ΔNp63 physically and functionally interact with distinct transcription factors for the downstream regulation of their target genes, thus ultimately leading to the regulation of unique transcriptional programs and biological processes. Our findings unveil novel transcriptomes regulated by the p63 isoforms to control diverse biological functions, including the cooperation between TAp63 and NRF2 in the modulation of metabolic pathways and response to oxidative stress providing a mechanistic explanation for the TAp63 knock out phenotypes. Significance: The p63 isoforms, TAp63 and ΔNp63, control epithelial morphogenesis and tumorigenesis through the interaction with distinct transcription factors and the subsequent regulation of unique transcriptional programs.

Year:

2024

Summary Integrative Module Analysis for Multi-omics Data ( iModMix ) is a biology-agnostic framework that enables the discovery of novel associations across any type of quantitative abundance data, including but not limited to transcriptomics, proteomics, and metabolomics. Instead of relying on pathway annotations or prior biological knowledge, iModMix constructs data-driven modules using graphical lasso to estimate sparse networks from omics features. These modules are summarized into eigenfeatures and correlated across datasets for horizontal integration, while preserving the distinct feature sets and interpretability of each omics type. iModMix operates directly on matrices containing expression or abundances for a wide range of features, including but not limited to genes, proteins, and metabolites. Because it does not rely on annotations ( e . g ., KEGG identifiers), it can seamlessly incorporate both identified and unidentified metabolites, addressing a key limitation of many existing metabolomics tools. iModMix is available as a user-friendly R Shiny application requiring no programming expertise ( https://imodmix.moffitt.org ), and as an R package for advanced users ( https://github.com/biodatalab/iModMix ). The tool includes several public and in-house datasets to illustrate its utility in identifying novel multi-omics relationships in diverse biological contexts. Availability and implementation Shiny application: https://imodmix.moffitt.org . The R package and source code: https://github.com/biodatalab/iModMix .

Year:

2024

Cysteine plays critical roles in cellular biosynthesis, enzyme catalysis, and redox metabolism. The intracellular cysteine pool can be sustained by cystine uptake or de novo synthesis from serine and homocysteine. Demand for cysteine is increased during tumorigenesis for generating glutathione to deal with oxidative stress. While cultured cells have been shown to be highly dependent on exogenous cystine for proliferation and survival, how diverse tissues obtain and use cysteine in vivo has not been characterized. We comprehensively interrogated cysteine metabolism in normal murine tissues and cancers that arise from them using stable isotope 13C1-serine and 13C6-cystine tracing. De novo cysteine synthesis was highest in normal liver and pancreas and absent in lung tissue, while cysteine synthesis was either inactive or downregulated during tumorigenesis. By contrast, cystine uptake and metabolism to downstream metabolites was a universal feature of normal tissues and tumors. However, differences in glutathione labeling from cysteine were evident across tumor types. Thus, cystine is a major contributor to the cysteine pool in tumors, and glutathione metabolism is differentially active across tumor types.

Year:

2024

Cysteine plays critical roles in cellular biosynthesis, enzyme catalysis, and redox metabolism. The intracellular cysteine pool can be sustained by cystine uptake or de novo synthesis from serine and homocysteine. Demand for cysteine is increased during tumorigenesis for generating glutathione to deal with oxidative stress. While cultured cells have been shown to be highly dependent on exogenous cystine for proliferation and survival, how diverse tissues obtain and use cysteine in vivo has not been characterized. We comprehensively interrogated cysteine metabolism in normal murine tissues and cancers that arise from them using stable isotope 13 C 1 -serine and 13 C 6 -cystine tracing. De novo cysteine synthesis was highest in normal liver and pancreas and absent in lung tissue, while cysteine synthesis was either inactive or downregulated during tumorigenesis. In contrast, cystine uptake and metabolism to downstream metabolites was a universal feature of normal tissues and tumors. However, differences in glutathione labeling from cysteine were evident across tumor types. Thus, cystine is a major contributor to the cysteine pool in tumors, and glutathione metabolism is differentially active across tumor types. Significance: Stable isotope 13 C 1 -serine and 13 C 6 -cystine tracing characterizes cysteine metabolism in normal murine tissues and its rewiring in tumors using genetically engineered mouse models of liver, pancreas, and lung cancers.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (16)

Walid Khaled

University lecturer

University of Cambridge

UNITED KINGDOM
View details

Thomas Park

Professor

University of Chicago

UNITED STATES
View details

Andrea Ventura

Member

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

yian Chen

Professor

University of Utah

UNITED STATES
View details

Ewan Smith

Head of Department

University of Cambridge

UNITED KINGDOM
View details

Christine Crish

Associate Professor (tenured)

Northeast Ohio Medical University

UNITED STATES
View details

Cristian Coarfa

Baylor College of Medicine

UNITED STATES
View details

Nicolas Prieto

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Marco Napoli

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Christopher T. Chen

Stanford University School of Medicine

UNITED STATES
View details

Paulo Rodriguez

Senior Member-Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Preethi Gunaratne

John & Rebecca Moores Professor

University of Houston

UNITED STATES
View details

Xiaoqing Yu

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Kenneth Tsai

Vice Chair of Research, Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paul Stewart

Research Associate Professor

University of Utah

UNITED STATES
View details